# Clinical assessment of transplacental transfer of maternal SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins: A chemiluminescence microparticle immunoassay study

**Authors:** Elora Sharmin, Ajmain Ishaat Khan, Sheikh Foyez Ahmed, Moises Leon Juarez, Etsuro Ito, Etsuro Ito

PMC · DOI: 10.1371/journal.pone.0336516 · PLOS One · 2025-11-13

## TL;DR

This study shows that maternal SARS-CoV-2 antibodies against the spike protein transfer efficiently to newborns, offering early protection, while antibodies against the nucleocapsid transfer less effectively.

## Contribution

The study provides empirical evidence on transplacental transfer of SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins in neonates.

## Key findings

- Maternal anti-S IgG had a higher placental transfer ratio (1.38) compared to anti-N IgG (1.13).
- A strong correlation was found between maternal and neonatal anti-S IgG levels.
- No significant associations were found between placental transfer ratios and maternal or neonatal factors like age or birth weight.

## Abstract

Understanding the safety and efficacy of COVID-19 vaccines in pregnant women and their neonates is crucial for understanding maternal and fetal outcomes, particularly the extent of passive immunity against SARS-CoV-2 which can be imparted to the neonates. The purpose of this study was to evaluate the transplacental transfer of maternal SARS-CoV-2 IgG antibodies against the spike (S) and nucleocapsid (N) proteins to neonates and understand whether factors like maternal comorbidities, gestational weeks, and neonatal birth weight have an influence on placental transfer ratios (PTR). A total of 57 pregnant women were assessed for SARS-CoV-2-specific IgG antibodies at delivery, and corresponding antibody titers were also measured in their neonates immediately after delivery. The PTRs for anti-S and anti-N IgG were calculated, and statistical analyses were performed for identifying potential influencing factors. The mean PTR for anti-S IgG was 1.38, suggesting effective placental transfer, whereas anti-N IgG had a lower PTR of 1.13, indicating limited transfer. A strong positive correlation was observed between maternal and neonatal anti-S IgG (r = 0.558, p < 0.01), whereas maternal and neonatal anti-N IgG correlated weakly (r = 0.402, p = 0.02). No significant associations were found between PTRs and maternal age, gestational weeks, neonatal birth weight, or comorbidities. Our study inferred the efficient transfer of maternal anti-S IgG, potentially conferring early neonatal immunity against SARS-CoV-2. However, the long-term persistence of these neonatal antibodies are questionable and remains an important research prospect. This study underscored the critical role of maternal vaccination for neonatal protection and can help form evidence based rational vaccination strategies for maximum neonatal protection.

## Linked entities

- **Proteins:** CHMP5 (charged multivesicular body protein 5)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** N (nucleocapsid phosphoprotein) [NCBI Gene 43740575], S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}
- **Diseases:** COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12614515/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12614515/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12614515/full.md

---
Source: https://tomesphere.com/paper/PMC12614515